Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell ImmunotherapiesGlobeNewsWire • 05/15/20
Editas Medicine, Inc. (EDIT) CEO Cynthia Collins on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20
Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor CancersGlobeNewsWire • 04/29/20
3 Stocks to Buy to Get a Big Bang for the Buck With Your Coronavirus Stimulus CheckThe Motley Fool • 04/15/20
Are Options Traders Betting on a Big Move in Editas Medicine (EDIT) Stock?Zacks Investment Research • 04/06/20
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/27/20
Why Biotech Stocks AnaptysBio, bluebird bio, and Editas Medicine Are Sinking TodayThe Motley Fool • 03/12/20
Editas and Allergan Make Gene-Editing History With First Treatment of Blindness DrugThe Motley Fool • 03/04/20
Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10GlobeNewsWire • 03/04/20
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20